Mannose-modified hyaluronic acid nanocapsules for the targeting of tumor-associated macrophages
Tumor-associated macrophages (TAMs), a class of immune cells that play a key role in tumor immunosuppression, are recognized as important targets to improve cancer prognosis and treatment. Consequently, the engineering of drug delivery nanocarriers that can reach TAMs has acquired special relevance. This work describes the development and biological evaluation of a panel of hyaluronic acid (HA) nanocapsules (NCs), with different compositions and prepared by different techniques, designed to target macrophages. The results showed that plain HA NCs did not significantly influence the polarization of M0 and M2-like macrophages towards an M1-like pro-inflammatory phenotype; however, the chemical functionalization of HA with mannose (HA-Man) led to a significant increase of NCs uptake by M2 macrophages in vitro and to an improved biodistribution in a MN/MNCA1 fibrosarcoma mouse model with high infiltration of TAMs. These functionalized HA-Man NCs showed a higher accumulation in the tumor compared to non-modified HA NCs. Finally, the pre-administration of the liposomal liver occupying agent Nanoprimer™ further increased the accumulation of the HA-Man NCs in the tumor. This work highlights the promise shown by the HA-Man NCs to target TAMs and thus provides new options for the development of nanomedicine and immunotherapy-based cancer treatments. Graphical abstract.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
|---|---|
| Enthalten in: |
Drug Delivery and Translational Research - 13(2022), 7 vom: 06. Dez., Seite 1896-1911 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Fernández-Mariño, Iago [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| BKL: |
58.28 / Pharmazeutische Technologie / Pharmazeutische Technologie |
|---|---|
| Themen: |
Cancer |
| Anmerkungen: |
© The Author(s) 2022 |
|---|
| doi: |
10.1007/s13346-022-01265-9 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC2143665954 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | OLC2143665954 | ||
| 003 | DE-627 | ||
| 005 | 20240410115436.0 | ||
| 007 | tu | ||
| 008 | 240118s2022 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s13346-022-01265-9 |2 doi | |
| 035 | |a (DE-627)OLC2143665954 | ||
| 035 | |a (DE-He213)s13346-022-01265-9-p | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 084 | |a PHARM |q DE-84 |2 fid | ||
| 084 | |a 15,3 |2 ssgn | ||
| 084 | |a 58.28 |2 bkl | ||
| 100 | 1 | |a Fernández-Mariño, Iago |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Mannose-modified hyaluronic acid nanocapsules for the targeting of tumor-associated macrophages |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a © The Author(s) 2022 | ||
| 520 | |a Tumor-associated macrophages (TAMs), a class of immune cells that play a key role in tumor immunosuppression, are recognized as important targets to improve cancer prognosis and treatment. Consequently, the engineering of drug delivery nanocarriers that can reach TAMs has acquired special relevance. This work describes the development and biological evaluation of a panel of hyaluronic acid (HA) nanocapsules (NCs), with different compositions and prepared by different techniques, designed to target macrophages. The results showed that plain HA NCs did not significantly influence the polarization of M0 and M2-like macrophages towards an M1-like pro-inflammatory phenotype; however, the chemical functionalization of HA with mannose (HA-Man) led to a significant increase of NCs uptake by M2 macrophages in vitro and to an improved biodistribution in a MN/MNCA1 fibrosarcoma mouse model with high infiltration of TAMs. These functionalized HA-Man NCs showed a higher accumulation in the tumor compared to non-modified HA NCs. Finally, the pre-administration of the liposomal liver occupying agent Nanoprimer™ further increased the accumulation of the HA-Man NCs in the tumor. This work highlights the promise shown by the HA-Man NCs to target TAMs and thus provides new options for the development of nanomedicine and immunotherapy-based cancer treatments. Graphical abstract | ||
| 650 | 4 | |a Cancer | |
| 650 | 4 | |a Hyaluronic acid | |
| 650 | 4 | |a Mannose | |
| 650 | 4 | |a Polymeric nanocapsules | |
| 650 | 4 | |a Nanoprimer | |
| 650 | 4 | |a Tumor-associated macrophages | |
| 700 | 1 | |a Anfray, Clément |0 (orcid)0000-0002-7118-974X |4 aut | |
| 700 | 1 | |a Crecente-Campo, Jose |0 (orcid)0000-0002-8630-5010 |4 aut | |
| 700 | 1 | |a Maeda, Akihiro |0 (orcid)0000-0003-4797-0314 |4 aut | |
| 700 | 1 | |a Ummarino, Aldo |0 (orcid)0000-0002-8623-0338 |4 aut | |
| 700 | 1 | |a Teijeiro-Valiño, Carmen |0 (orcid)0000-0003-1838-1764 |4 aut | |
| 700 | 1 | |a Blanco-Martinez, Dario |4 aut | |
| 700 | 1 | |a Mpambani, Francis |4 aut | |
| 700 | 1 | |a Poul, Laurence |4 aut | |
| 700 | 1 | |a Devalliere, Julie |4 aut | |
| 700 | 1 | |a Germain, Matthieu |4 aut | |
| 700 | 1 | |a Correa, Juan |4 aut | |
| 700 | 1 | |a Fernandez-Villamarin, Marcos |4 aut | |
| 700 | 1 | |a Allavena, Paola |0 (orcid)0000-0002-6697-6028 |4 aut | |
| 700 | 1 | |a Fernandez-Megia, Eduardo |0 (orcid)0000-0002-0405-4933 |4 aut | |
| 700 | 1 | |a Alonso, María José |0 (orcid)0000-0001-7187-9567 |4 aut | |
| 700 | 1 | |a Andón, Fernando Torres |0 (orcid)0000-0001-9235-1278 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Drug Delivery and Translational Research |d Springer US, 2011 |g 13(2022), 7 vom: 06. Dez., Seite 1896-1911 |w (DE-627)767568605 |w (DE-600)2732593-3 |w (DE-576)393435571 |x 2190-393X |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2022 |g number:7 |g day:06 |g month:12 |g pages:1896-1911 |
| 856 | 4 | 1 | |u https://doi.org/10.1007/s13346-022-01265-9 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a FID-PHARM | ||
| 912 | |a SSG-OPC-PHA | ||
| 912 | |a SSG-OPC-DE-84 | ||
| 936 | b | k | |a 58.28 |j Pharmazeutische Technologie |j Pharmazeutische Technologie |q VZ |
| 951 | |a AR | ||
| 952 | |d 13 |j 2022 |e 7 |b 06 |c 12 |h 1896-1911 | ||